- Home
- / Jounce Therapeutics
Jounce Therapeutics
Stock Price
$1.9
2023-05-05
Market Capitalization
$101.6 M
2023-05-05
Jounce Therapeutics Summary
Company Summary
- Overview
- Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies biomarkers to match the right therapy.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://jouncetx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Hugh Cole, Chief Operating Officer
Kim Drapkin, Chief Financial Officer
Jacqui Fahey Sandell, Chief Legal Officer and Corporate Secretary
LocationsView all
1 location detected
Cambridge, MA HQ
United States
780 Memorial Dr
Jounce Therapeutics Financials
Summary Financials
- Net income (FY, 2022)
- ($50.9M)
- Cash (FY, 2022)
- $150.6M
- EBIT (FY, 2022)
- ($52.2M)
- Enterprise value
- ($39.0M)